In an interview with ONCOLOGY®, Keith Hecht, PharmD, offers a comprehensive review of real-world treatment considerations of loncastuximab tesirine as therapy for patients with diffuse large B-cell lymphoma.
Keith Hecht, PharmD
Advertisement
Articles by Keith Hecht, PharmD
Advertisement
Latest Updated Articles
Expert Commentary on the Product Profile of Loncastuximab TesirinePublished: December 16th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
2
Career Stage and Location Found to Impact Oncology Coverage in the US
3
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
4
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
5
